Nunzio Filardi

Learn More
BACKGROUND The prognosis of patients with plasma cell leukemia (PCL), an aggressive variant of multiple myeloma (MM), is usually poor. Bortezomib is the first proteasome inhibitor approved for the treatment of advanced MM. Currently available information regarding the role of bortezomib in PCL is scanty and derives from anecdotal, single-case reports. (More)
OBJECTIVE Azacitidine is the standard of care for higher-risk myelodysplastic syndromes (MDS). We evaluated factors affecting the outcome of azacitidine treatment in 196 'real-world' patients, retrospectively collected by two Italian cooperative groups. METHODS The study included 184 MDS and 12 low blast count acute myeloid leukemia (AML). Azacitidine was(More)
treatment for cytosine arabinoside-induced keratoconjunctivitis. Topical prophylaxis of conjunctivitis induced by high-dose cytosine arabinoside. The use of prophylactic eye drops during high-dose cytosine arabinoside therapy. Primary plasma cell leukemia (PPCL) carries a very severe prognosis. 1 Retrospective reviews revealed a response rate to(More)
The Hema e-Chart prospectively collected data on febrile events (FEs) in hematological malignancy patients (HMs). The aim of the study was to assess the number, causes and outcome of HM-related FEs. Data were collected in a computerized registry that systematically approached the study and the evolution of FEs developing in a cohort of adult HMs who were(More)
  • 1